On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This makes Zepbound the only drug in history to be approved specifically for OSA — a condition that affects an estimated 30 million Americans and has, until now, been
